ProfileGDS5678 / 1451830_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 72% 70% 69% 70% 71% 71% 69% 70% 72% 73% 70% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4289371
GSM967853U87-EV human glioblastoma xenograft - Control 24.5526872
GSM967854U87-EV human glioblastoma xenograft - Control 34.3643370
GSM967855U87-EV human glioblastoma xenograft - Control 44.3329369
GSM967856U87-EV human glioblastoma xenograft - Control 54.342970
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4561571
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4161271
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2898469
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3675270
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5681172
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6378573
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3636770
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.431971
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4196471